Durable tumor regression in highly refractory metastatic KIT/PDGFRA wild-type GIST following treatment with nivolumab

Gastrointestinal stromal tumor (GIST) is a devastating disease, especially in the setting of metastasis. The natural progression of GIST has been significantly altered by the development of small molecule tyrosine kinase inhibitors (TKIs), including imatinib, sunitinib, and regorafenib, all of which...

Descripción completa

Detalles Bibliográficos
Autores principales: Schroeder, Brett A., Kohli, Karan, O’Malley, Ryan B., Kim, Theresa S., Jones, Robin L., Pierce, Robert H., Pollack, Seth M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959429/
https://www.ncbi.nlm.nih.gov/pubmed/32002307
http://dx.doi.org/10.1080/2162402X.2019.1710064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959429/
https://www.ncbi.nlm.nih.gov/pubmed/32002307
http://dx.doi.org/10.1080/2162402X.2019.1710064

Ejemplares similares